(Q44177895)

English

Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).

scientific article published in October 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

I Radman

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

N Basić

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

B Labar

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J Kovacević

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

I Aurer

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

V Bogdanić

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

S Zupancić-Salek

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

D Nemet

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J Jakić-Razumović

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Mrsić

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

F Santek

11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

L Grgić-Markulin

12

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

D Boban

13

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1650-1655

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Leukemia following Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

ESHAP is an active regimen for relapsing Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

VIM-D salvage chemotherapy in Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Lung cancer in Hodgkin's disease: association with previous radiotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

MiCMA: an alternative treatment for refractory or recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

High dose chemotherapy with G-CSF in refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF271

21 January 2018

Identifiers

10.1093/ANNONC/MDF271

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44177895&oldid=2108301215"